Header

UZH-Logo

Maintenance Infos

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration


Ference, Brian A; Cannon, Christopher P; Landmesser, Ulf; Lüscher, Thomas F; Catapano, Alberico L; Ray, Kausik K (2018). Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. European Heart Journal, 39(27):2540-2545.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

41 downloads since deposited on 26 Feb 2018
41 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Cardiology and Cardiovascular Medicine
Language:English
Date:2018
Deposited On:26 Feb 2018 21:45
Last Modified:19 Aug 2018 14:56
Publisher:Oxford University Press
ISSN:0195-668X
OA Status:Hybrid
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/eurheartj/ehx450
PubMed ID:29020411

Download

Download PDF  'Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration'.
Preview
Content: Published Version
Filetype: PDF
Size: 360kB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)